Larotrectinib and Entrectinib: TRK Inhibitors for the Treatment of Pediatric and Adult Patients With NTRK Gene Fusion
Danielle B. Dunn
Abstract
gene fusion is now a targetable biomarker for patients who may otherwise be devoid of satisfactory alternative treatment options. In this article, the safety and efficacy trials of each medication, and the initial and ongoing monitoring required for patients on these treatments will be discussed.
Topics & Concepts
Trk receptorMedicineFusion geneGeneBioinformaticsInternal medicineReceptorGeneticsNeurotrophinBiologyLung Cancer Treatments and MutationsNeuroblastoma Research and TreatmentsPI3K/AKT/mTOR signaling in cancer